July 21, 2016 4:55pm

… Shorts create a downside pattern as traders turned-up volatility

My pre-open indications – 4 hit (JUNO, KITE, PSTI and XON) and 0 miss

 

I answer one question; in which company should investors put, keep and commit their money!

 

Do you care what happened today, you should … because it has implications to Friday's sector activity?  

Where has today’s market gone – subscribe and find out. 

 

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

U.S. stocks closed lower Thursday, snapping the Dow's nine-day winning streak, as oil prices weighed and the market consolidated ahead of next week's Fed meeting.

The NASDAQ closed DOWN -16.03 or -0.31% to 5,073.90 and the DOW closed DOWN -77.80 or -0.42% to 18,517.23.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:    

  • The open was positive with an A/DL of 27/12 and 4 flats;
  • The mid-day stayed positive with an A/DL of 21/18 and 4 flats;
  • 3 pm tripped negative with an A/DL of  18/24 and 1 flat;
  • The closing bell was negative with A/DL of 19/22 and 2 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened positive, stayed positive at the mid-day, slipped negative a 3 pm and closed negative.

  • As I had stated yesterday … “Don’t be deceived by another high in the sector and market only to find that traders are just salivating at the volatility and low volume.”

As usual, there are a number of indicators – volatility, low volume and the squeezing of advance/decline lines pointing in opposite directions.

 

A more ominous indicator regarding the SCG&RT sector is – never be long over a hot summer weekend when one can leave with a quarter in your pocket!

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Thursday traded near 12.73;
  • Wednesday traded near 11.72;
  • Tuesday near 12.6;
  • Monday traded near 12.4;
  • Friday closed near 13;
  • Last, Thursday closed below 13;

 

 

Today’s Bottom Line:

Sticks and stones will break my bones but, trading “names” with a profit will never hurt me!

 

 

My pre-open indications – 4 hits and 0 miss:

  • Intrexon (XON) closed DOWN -$0.22 – hit;
  • Juno Therapeutics (JUNO) closed UP +$0.18 – hit;
  • Kite Pharma (KITE) closed UP +$0.36 – hit;
  • Pluristem (PSTI) closed DOWN -$0.02 – hit;

 

 

Largest decliners:

  • Brainstorm (BCLI) -6.27%;
  • AxoGen (AXGN) -6.64%;
  • Organovo (ONVO) -4.29% after yesterday’s+8.68%;
  • VistaGen (VTGN) -4.22% after Wednesday’s +7.23% and Tuesday’s -5.39%;
  • Athersys (ATHX) -2.75%

 

Advancers:

  • International Stem cell (ISC) +10.51% after yesterday’s -9.74% after Tuesday’s +11.43%;
  • BioLife Solutions (BLFS) +7.69%;
  • Fibrocell (FCSC) +5.66% after yesterday’s -7.02% post Tuesday’s -6.56%;
  • Regenxbio (RGNX) +4.25%;
  • ImmunoCellular (NYSEMKT: IMUC) +4.24% or +$0.00085;

 

Flat:                                                                                                                                      

  • Adverum (ADVM) at $3.05;
  • ReNeuron (RENE.L) at $3.00;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.